Donafenib
Clinical data | |
---|---|
Trade names | Zepsun |
Other names | CM-4307 |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H16ClF3N4O3 |
Molar mass | 464.83 g·mol−1 |
3D model (JSmol) | |
| |
|
Donafenib, sold under the brand name Zepsun, is a pharmaceutical drug for the treatment of cancer.
In China, donafenib is approved for the treatment of unresectable hepatocellular carcinoma in patients who have not previously received systemic treatment.[1][2]
Donafenib is a multikinase inhibitor that targets Raf kinase and various receptor tyrosine kinases.[3] It is a deuterated derivative of sorafenib with improved pharmacokinetic properties.[4][5]
References[edit]
- ^ Keam, Susan J.; Duggan, Sean (2021). "Donafenib: First Approval". Drugs. 81 (16): 1915–1920. doi:10.1007/s40265-021-01603-0. PMID 34591285.
- ^ Chen, Rusi; Ielasi, Luca; Di Carlo, Alma; Tovoli, Francesco (2023). "Donafenib in hepatocellular carcinoma". Drugs of Today. 59 (2): 83–90. doi:10.1358/dot.2023.59.2.3507751. PMID 36811408.
- ^ "Donafenib". NCI Cancer Dictionary. National Cancer Institute, National Institutes of Health.
- ^ Qin, Shukui; Bi, Feng; Gu, Shanzhi; Bai, Yuxian; Chen, Zhendong; Wang, Zishu; Ying, Jieer; Lu, Yinying; Meng, Zhiqiang; Pan, Hongming; Yang, Ping; Zhang, Helong; Chen, Xi; Xu, Aibing; Cui, Chengxu; Zhu, Bo; Wu, Jian; Xin, Xiaoli; Wang, Jufeng; Shan, Jinlu; Chen, Junhui; Zheng, Zhendong; Xu, Li; Wen, Xiaoyu; You, Zhenyu; Ren, Zhenggang; Liu, Xiufeng; Qiu, Meng; Wu, Liqing; Chen, Feng (2021). "Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial". Journal of Clinical Oncology. 39 (27): 3002–3011. doi:10.1200/JCO.21.00163. PMC 8445562. PMID 34185551.
- ^ Qin, S.; Bi, F.; Xu, J.; Du, C.; Fan, Q.; Zhang, L.; Tao, M.; Jiang, D.; Wang, S.; Chen, Y.; Sheng, J.; Zhuang, X.; Wu, J.; Lv, B. (2020). "P-86 Comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma: An open-label, randomized, parallel-controlled, multicentre phase II/III trial". Annals of Oncology. 31: S117–S118. doi:10.1016/j.annonc.2020.04.168.